Core Viewpoint - Silo Pharma, Inc. has announced a public offering of 3,333,338 shares of common stock at a price of $0.60 per share, along with associated warrants, aiming to raise approximately $2 million for general working capital purposes [1][2]. Group 1: Offering Details - The public offering includes 3,333,338 shares of common stock and two series of warrants (Series A-1 and Series A-2), each with an exercise price of $0.60 per share [1]. - The Series A-1 Warrants are exercisable upon issuance and will expire five years thereafter, while the Series A-2 Warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected to occur on or about May 16, 2025, subject to customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are expected to be approximately $2 million before deducting fees and expenses [2]. - The net proceeds will be used for general working capital purposes [2]. Group 3: Company Overview - Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [5]. - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]. - Research is conducted in collaboration with leading universities and laboratories [5].

SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress ...

Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization), for a Food and Drug Administration (FDA) requested 7 ...

For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41512 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) | Nevada | 27-3046338 | | --- | --- ...

Core Viewpoint - Silo Pharma, Inc. announced positive preclinical results for SP-26, an extended-release ketamine implant, indicating its potential as a safe and effective treatment for fibromyalgia [1][2]. Study Results - All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation [2]. - No implant-related adverse events were observed, with animals maintaining a healthy weight and normal neurological behavior throughout the study [3]. - Ketamine was steadily released post-implantation, achieving peak drug levels within 1 hour and sustaining plasma concentrations for up to 22 days [3]. Safety and Tolerability - Both SP-26 formulations elicited only minimal to mild chronic inflammation at the implant sites, with no significant differences based on dose or formulation [4]. - The design of SP-26 aims to provide sustained, sub-psychedelic levels of ketamine in an abuse-deterrent format, aligning with FDA safety requirements for potential at-home therapeutic designation [5]. Product Overview - SP-26 is a ketamine-based injectable dissolvable polymer implant intended for chronic pain and fibromyalgia treatment, designed to regulate dosage and time release safely [5]. - If clinically successful, SP-26 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval [5]. Company Background - Silo Pharma Inc. focuses on addressing underserved conditions, including chronic pain and psychiatric disorders, with a portfolio that includes programs for PTSD and preclinical assets targeting Alzheimer's disease and multiple sclerosis [6].

Core Insights - Silo Pharma, Inc. has filed a patent application for its neurology drug SPC-14, aimed at treating Alzheimer's disease, which is exclusively licensed from Columbia University [1][3] Patent Details - The patent titled "Compositions and Methods for the Treatment of Alzheimer's Disease and Other Neurogenerative Disease" focuses on SPC-14's mechanism of action, targeting glutamate receptor NDMAR and serotonin 5-HT4 to alleviate cognitive and neuropsychiatric symptoms in Alzheimer's disease [2][4] Drug Development - Early pre-clinical studies indicate that SPC-14 has the potential to improve cognitive memory function [3] - The drug has shown efficacy in preclinical studies against luteinizing hormone (LH) stress, reducing learned helplessness, perseverative behavior, and hyponeophagia, which is a measure of anxiety [4] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company that focuses on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [5] - The company's portfolio includes other innovative programs such as SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain, alongside preclinical assets targeting Alzheimer's disease and multiple sclerosis [5]

The SS25 collection will be available globally on April 17NEW YORK, April 17, 2025 /PRNewswire/ -- Saucony, a global performance running and lifestyle brand, today revealed the details behind Saucony SILO, its elevated footwear collection blending the brand's rich heritage and technology with high-fashion influences. Challenging the expectations of traditional luxury sneakers, the collection incorporates premium materials and a fresh, refined approach to some of Saucony's most iconic designs. With an emphas ...

Revenue and Loss - The company generated minimal revenues of $72,102 for both the years ended December 31, 2024 and 2023, related to the Aikido License and Sublicense Agreement [251]. - The net loss for the year ended December 31, 2024, was $4,392,880, compared to a net loss of $3,700,683 in 2023, reflecting an increase in losses [250]. - Net loss amounted to $4,392,880 in 2024, or $1.19 per common share, compared to a net loss of $3,700,683 or $1.20 per common share in 2023, an increase of $692,197 or 18.7% [263]. - Loss from continuing operations increased to $4,705,694 in 2024 from $3,855,592 in 2023, an increase of $850,102 or 22.1% [259]. - As of December 31, 2024, the company had an accumulated deficit of $15,264,691 [272]. Operating Expenses - Total operating expenses increased to $4,771,958 in 2024 from $3,921,856 in 2023, representing a rise of 21.8% [253]. - Compensation expenses increased by 4.0% to $906,773 in 2024, primarily due to higher health insurance and executive bonus payments [255]. - Selling, general and administrative expenses decreased to $298,284 in 2024 from $479,078 in 2023, a reduction of $180,794 or 37.7% [258]. Research and Development - Research and development expenses surged to $2,368,156 in 2024, up from $845,092 in 2023, indicating a significant focus on product development [253]. - Research and development expenses increased to $2,368,156 in 2024 from $845,092 in 2023, a rise of $1,523,064 or 180.2% [256]. - The company is developing SPC-15, an intranasal drug for PTSD and anxiety disorders, with a pre-IND meeting held with the FDA in September 2024 [237]. - SP-26, a ketamine-based implant for fibromyalgia, is currently in preclinical research, with initial animal studies evaluating its dosage and time release [240]. - SPC-14 targets Alzheimer's disease and is projected to tap into a global therapeutics market expected to exceed $30.8 billion by 2033 [244]. - The company has entered into a license agreement with the University of Maryland for a ketamine polymer implant and a sponsored research agreement with Columbia University for Alzheimer's treatment [235]. Cash Flow and Working Capital - Working capital decreased to $5,455,483 in 2024 from $6,905,568 in 2023, a decline of $1,450,085 or 21% [265]. - Net cash used in operating activities increased to $3,833,914 in 2024 from $3,224,498 in 2023, an increase of $609,416 or 18.9% [267]. - Net cash provided by investing activities was $973,777 in 2024, a positive change of $5,120,884 or 123.5% from $(4,147,107) in 2023 [269]. - Net cash provided by financing activities was $3,241,628 in 2024, a positive change of $3,712,749 or 788% from $(471,121) in 2023 [270]. - The company believes it has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing [273]. Stock Repurchase - The stock repurchase plan authorized the repurchase of up to $1 million of common stock, with 355,710 shares repurchased at a total cost of $644,234 during 2023 and 2024 [248].

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for p ...

Core Insights - Silo Pharma, Inc. announced the issuance of a patent for pharmacological prophylactics against stress-induced affective disorders in females, with the patent number projected to be 12,239,614, effective March 4, 2025 [1][2][3] Patent and Product Development - The new patent reinforces protection for Silo's lead asset, SPC-15, which is an intranasal treatment targeting post-traumatic stress disorder (PTSD) and includes newly added claims to an existing patent [2][3] - SPC-15 is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders, with potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, which could accelerate the approval process [4] Strategic Collaborations - Silo Pharma is collaborating with Columbia University to conduct preclinical studies for SPC-15, and the company holds exclusive global rights for its development and commercialization [4][5] - The CEO emphasized that strategic IP and patent expansion is crucial for advancing SPC-15 to clinical trials and enhancing the overall value of the company's pipeline [3]